A second course of radium-223 was associated with minimal hematologic toxicity and low radiographic bone progression rates in a phase I/II study of men with metastatic castration-resistant prostate cancer.
Tanya B. Dorff, MD, discusses several important components regarding metastatic castration-resistant prostate cancer treatment, including the addition of novel drugs, optimal therapeutic sequences, and the identification of predictive biomarkers.
Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.
Rucaparib, a drug approved for the treatment of ovarian cancer, might also be used to treat patients with metastatic castration-resistant prostate cancer.
A new drug application has been submitted to the FDA for apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC).
The FDA has approved a cabazitaxel (Jevtana) regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer.
Results of an investigation indicate that resistance to docetaxel and cabazitaxel (Jevtana) in patients with castration-resistant prostate cancer is mediated by a common mechanism, overexpression of the ABCB1 gene.
Astellas Pharma and Pfizer have announced that phase III results from the PROSPER trial of enzalutamide (Xtandi) in men with nonmetastatic castration-resistant prostate cancer will be ready later this year.
A recent phase II trial demonstrated that the combination of docetaxel-based chemotherapy and dexamethasone showed significantly high PSA responses compared with previous studies in patients with CRPC.
Raoul S. Concepcion, MD, discusses the new era of molecular testing and screening and how it has impacted the field of prostate cancer thus far.